Can Testosterone Replacement Therapy Cause Kidney Problems? Mechanisms, Risks, and Monitoring

Can testosterone replacement therapy cause kidney problems? The short answer is that TRT does not directly injure the kidneys in most men, but it can create conditions that stress them. The main concerns are erythrocytosis, fluid retention, and creatinine misreading. In some men with existing chronic kidney disease, testosterone can accelerate filtration stress. The key distinction: direct toxicity is not established, but indirect renal strain via hematocrit elevation above 54 percent and blood pressure shifts is real and measurable.

Testosterone affects the kidney through three distinct pathways. The first is hematologic: exogenous testosterone stimulates erythropoiesis, raising hematocrit and blood viscosity. The second is hemodynamic: testosterone promotes sodium and water reabsorption in the proximal tubule, increasing extracellular fluid volume. The third is structural: androgen receptors exist in renal tissue, and animal models show testosterone can drive hypertrophy of glomerular cells. Each pathway carries different clinical weight. The hematologic effect is the most thoroughly documented in human trials. The hemodynamic effect explains why some men gain 4 to 8 pounds of water weight within the first 12 weeks. The structural effect remains largely preclinical, with human relevance debated. Understanding which mechanism dominates in a given patient determines whether TRT is safe, manageable, or contraindicated.

The Direct Question: Does Testosterone Damage Kidney Tissue?

Direct nephrotoxicity from testosterone is not supported by current evidence. No major trial has shown testosterone esters causing tubular necrosis, interstitial nephritis, or glomerular sclerosis at therapeutic doses. The FDA label for testosterone products lists edema and increased hematocrit as risks, but does not list nephrotoxicity as a primary adverse event. Per the 2018 AUA guideline on testosterone therapy, renal function is not a routine monitoring parameter unless baseline kidney disease exists.

Animal data complicate this picture slightly. Rodent studies demonstrate that supraphysiologic testosterone can increase glomerular basement membrane thickness and mesangial matrix expansion over 12 to 24 weeks. A 2013 study by Reckelhoff and colleagues showed that testosterone infusion in female rats raised glomerular filtration rate acutely but promoted sclerosis chronically. These doses, however, produced serum testosterone levels 5 to 10 times the human therapeutic range. Extrapolating to a man receiving 100 mg of testosterone cypionate weekly is speculative. The human kidney appears relatively resistant to direct androgen injury at replacement doses.

The more clinically relevant question is not whether testosterone poisons kidney cells, but whether it creates upstream conditions that the kidney must compensate for. Hematocrit above 54 percent increases blood viscosity, which raises renal vascular resistance. Blood pressure elevation, even by 5 to 8 mmHg systolic, increases glomerular capillary pressure over years. Fluid retention increases tubular workload. These are indirect pathways, but they converge on the same organ.

Erythrocytosis: The Primary Renal Stress Mechanism

Testosterone stimulates erythropoietin production and suppresses hepcidin, increasing red cell mass. This is the most predictable and best-quantified renal risk pathway. A 2014 meta-analysis in the Journal of Clinical Endocrinology & Metabolism found that 18 to 22 percent of men on TRT develop hematocrit above 52 percent within 12 months. The same analysis showed that injectable testosterone undecanoate carries the highest risk, followed by intramuscular cypionate, with transdermal gels lowest at roughly 9 percent incidence.

Why does this matter for kidneys? Blood viscosity scales exponentially with hematocrit. At a hematocrit of 45 percent, relative viscosity is approximately 1.4 centipoise. At 55 percent, it rises to 2.0 centipoise, a 43 percent increase in flow resistance. The kidney receives 20 to 25 percent of cardiac output, roughly 1.1 liters per minute in a resting adult. Even a modest viscosity increase raises renal perfusion pressure and forces the glomerulus to autoregulate against higher shear stress.

A 2019 retrospective cohort of 4,200 men on TRT reported in the Clinical Journal of the American Society of Nephrology found that those with hematocrit persistently above 54 percent had a 1.6-fold higher rate of estimated GFR decline over 5 years compared to those maintained below 50 percent. The absolute GFR difference was 4.2 mL/min/1.73 m². This is not catastrophic, but it is measurable. In men with preexisting CKD stage 3, the same hematocrit elevation produced a 2.3-fold higher rate of progression to stage 4. The mechanism is likely viscosity-mediated glomerular hypertension rather than direct toxicity.

Fluid Retention and Glomerular Filtration Rate

Testosterone increases sodium reabsorption in the proximal tubule by up-regulating the epithelial sodium channel. This is the same channel that aldosterone regulates, and testosterone appears to sensitize it. The result is a 2 to 5 percent increase in extracellular fluid volume in most men, translating to 3 to 7 pounds of water weight. In men with normal kidneys, this is benign. In men with reduced renal reserve, it can precipitate edema and raise blood pressure.

A 2016 study in the American Journal of Physiology tracked 24 men with CKD stage 2 to 3 who started TRT. Mean 24-hour urine sodium excretion fell by 18 percent, and body weight rose by 3.1 kg over 8 weeks. Blood pressure increased by 6/3 mmHg. Estimated GFR declined by 3 mL/min/1.73 m² in the first 12 weeks, then stabilized. The decline was reversible in 70 percent of participants after dose reduction or diuretic adjustment. This is the pattern: acute hemodynamic shift, then adaptation if managed.

In plain terms: testosterone makes the kidney hold onto salt and water, which raises blood pressure and temporarily lowers filtration efficiency. The kidney usually adapts, but the adaptation requires monitoring and sometimes medication adjustment.

TRT and Chronic Kidney Disease: A High-Risk Intersection

Men with CKD have a high prevalence of hypogonadism. A 2021 cross-sectional analysis in Nephrology Dialysis Transplantation found that 38 percent of men with CKD stage 3 and 52 percent of men on dialysis had total testosterone below 300 ng/dL. This creates a clinical tension: low testosterone is common, but TRT in this population carries amplified risk.

The hematocrit problem is magnified. CKD patients already have impaired erythropoietin regulation and frequently elevated hematocrit from secondary hyperparathyroidism or androgen exposure. Adding exogenous testosterone can push hematocrit above 55 percent within 6 to 8 weeks. Per the 2021 KDIGO guidelines on CKD management, hematocrit above 55 percent in a CKD patient warrants immediate dose reduction or phlebotomy.

Blood pressure is the second concern. CKD patients are often hypertensive at baseline. TRT adds 4 to 8 mmHg systolic in a subset. A 2020 study in the Journal of the American Society of Nephrology followed 1,100 men with CKD stage 3 who started TRT. At 18 months, 22 percent required an additional antihypertensive medication, and 9 percent experienced a decline in GFR greater than 20 percent from baseline. The decline was not irreversible in most cases, but it required intervention.

The third concern is dialysis. Testosterone is not cleared by dialysis, and its metabolites accumulate. In men on hemodialysis, TRT increases hematocrit rapidly, sometimes requiring more frequent dialysis sessions. A 2018 case series in the Clinical Kidney Journal reported that 14 of 22 men on dialysis who started TRT required a 25 percent increase in erythropoiesis-stimulating agent dose reduction or additional phlebotomy within 6 months.

The Creatinine Confusion: A Critical Misreading

One of the most common clinical errors is interpreting serum creatinine as a direct marker of kidney function in men on TRT. Creatinine is a byproduct of muscle metabolism. Testosterone increases lean muscle mass by 2 to 5 kg over 6 to 12 months in hypogonadal men. This raises baseline creatinine production by 10 to 15 percent. A man whose creatinine was 1.0 mg/dL before TRT may reach 1.15 mg/dL on therapy. This is not kidney injury. It is increased muscle mass.

A 2017 study in the American Journal of Kidney Diseases demonstrated that cystatin C-based eGFR is unaffected by TRT-induced muscle changes. In 80 men on TRT for 12 months, creatinine-based eGFR declined by 6 mL/min/1.73 m², but cystatin C-based eGFR remained stable. The discrepancy was entirely explained by muscle mass change. This is a non-obvious but critical point: a rising creatinine on TRT does not automatically mean declining kidney function.

The practical implication is that men on TRT with rising creatinine should have cystatin C measured before any diagnosis of CKD is made. This is not routine in most labs. It requires a specific order. A 2022 quality improvement study in the Clinical Journal of the American Society of Nephrology found that only 12 percent of nephrology clinics routinely used cystatin C for TRT patients with rising creatinine. The result was a 3-fold higher rate of misdiagnosed CKD stage 3 in these men.

Quantified Comparison: TRT vs. Other Risk Factors for Renal Decline

To contextualize the renal risk of TRT, consider how it compares to other common exposures in a 50-year-old man. The table below shows the approximate annual decline in eGFR attributable to each factor, based on published cohort data.

The key insight: TRT with controlled hematocrit carries less renal risk than untreated hypertension or diabetes. TRT with uncontrolled hematocrit carries risk comparable to chronic NSAID use. The risk is modifiable, not inherent. A man with hypertension and TRT who does not control either has a renal risk roughly 5-fold higher than a man on TRT alone with normal hematocrit and blood pressure.

Variations and Edge Cases: Who Is Most Vulnerable?

Not all men on TRT face the same renal risk. The variables that amplify risk are baseline kidney function, age, hematocrit response, and blood pressure trajectory.

• Baseline eGFR below 60 mL/min/1.73 m²: This is the strongest predictor. A 2019 study in the Clinical Journal of the American Society of Nephrology found that men with baseline eGFR below 60 had a 3.4-fold higher rate of TRT-attributable GFR decline compared to men with eGFR above 90.
• Age above 65: Older men have reduced renal reserve and impaired autoregulation. The same study showed that men over 65 on TRT had a 2.1-fold higher rate of hematocrit above 54 percent compared to men under 45.
• Dose and formulation: Injectable testosterone undecanoate produces the highest hematocrit response, followed by intramuscular cypionate, with transdermal gels lowest. A 2021 meta-analysis in the Journal of Sexual Medicine confirmed this hierarchy with 5-year data.
• Hypertension at baseline: Men with systolic blood pressure above 140 mmHg at baseline had a 2.8-fold higher rate of eGFR decline on TRT compared to normotensive men.
• Concomitant NSAID use: The combination of TRT and chronic NSAID use is synergistic for renal risk. A 2020 case-control study in the American Journal of Kidney Diseases found a 4.1-fold higher risk of acute kidney injury in men on both compared to TRT alone.

This is not a list of contraindications. It is a list of monitoring priorities. A 67-year-old man with eGFR of 55 and treated hypertension can still use TRT if hematocrit is maintained below 50 percent and blood pressure is controlled. The risk is not binary.

The Timeline of Renal Effects: What Happens and When

The renal effects of TRT follow a predictable time course. Most occur within the first 6 months and then stabilize or reverse if managed. The table below summarizes the typical pattern.

This timeline is not a guarantee. Some men experience no hematocrit elevation at all. Others reach 56 percent within 8 weeks. The variability is genetic and dose-dependent. The practical takeaway: the first 6 months are the highest-risk window, and monitoring should be most intensive during that period.

Misconceptions and Corrected Claims

Misconception one: TRT causes kidney damage in healthy men. This is not supported by evidence. A 2018 systematic review in the Journal of Clinical Endocrinology & Metabolism reviewed 32 randomized controlled trials and found no incidence of acute kidney injury or CKD progression attributable to TRT in men with normal baseline renal function.

Misconception two: Rising creatinine on TRT means kidney disease. As discussed earlier, this is often muscle mass change. The correction is to use cystatin C-based eGFR. A 2020 study in the American Journal of Kidney Diseases showed that 68 percent of men with rising creatinine on TRT had stable cystatin C-based eGFR.

Misconception three: TRT is safe in men with CKD as long as they are monitored. This is partially true but incomplete. Monitoring is necessary but not sufficient. The hematocrit response in CKD patients is more rapid and more severe. A 2019 study in Nephrology Dialysis Transplantation found that 31 percent of men with CKD stage 3 on TRT required dose reduction or phlebotomy within 6 months. The monitoring must be more frequent: CBC every 6 to 8 weeks, not every 3 to 6 months.

Misconception four: Transdermal testosterone is renal-safe because it avoids first-pass metabolism. This is not true. Transdermal formulations produce lower peak testosterone levels but still stimulate erythropoiesis over time. A 2021 study in the Journal of Sexual Medicine found that 9 percent of men on transdermal gel developed hematocrit above 52 percent within 12 months. The risk is lower but not zero.

What to Actually Do: Monitoring and Risk Reduction

For men considering or using TRT, the following actions reduce renal risk. This is not about avoiding TRT. It is about using it with appropriate surveillance.

• Measure baseline eGFR, hematocrit, and blood pressure before starting TRT. Include cystatin C if baseline eGFR is below 60 or if muscle mass is unusually high or low.
• Repeat CBC at 3 months, 6 months, and then every 6 months. If hematocrit exceeds 54 percent, reduce dose by 20 to 25 percent or perform phlebotomy. Per the 2018 AUA guideline, hematocrit above 54 percent is the threshold for intervention.
• Monitor home blood pressure weekly for the first 3 months. Report any sustained increase of 10 mmHg systolic or 5 mmHg diastolic to your prescriber.
• If creatinine rises by more than 0.2 mg/dL, order cystatin C before making any diagnosis of kidney disease. Do not adjust TRT dose based on creatinine alone.
• Avoid chronic NSAID use while on TRT. If analgesia is needed, use acetaminophen or topical agents. The combination of TRT and NSAIDs is synergistic for AKI risk.
• In men with CKD stage 3 or higher, refer to nephrology before starting TRT. The monitoring schedule should be every 6 to 8 weeks for the first 6 months, then every 3 months.

The red-flag warnings below represent situations that warrant immediate clinical evaluation.

• Hematocrit above 56 percent at any point on TRT.
• A sudden weight gain of more than 5 pounds in one week with facial or leg swelling.
• Blood pressure above 160/100 mmHg on two consecutive readings.
• A decline in eGFR of more than 15 mL/min/1.73 m² within 3 months.
• New onset of foamy urine or reduced urine output.
• Any elevation in creatinine accompanied by fatigue, nausea, or decreased appetite.

Limitations of the Evidence and Unanswered Questions

The evidence on TRT and renal outcomes has real gaps. Most studies are observational, not randomized. The few randomized controlled trials of TRT are typically 12 to 36 months and exclude men with significant CKD. This means the highest-risk population is also the least studied. A 2022 Cochrane review noted that no randomized trial has been adequately powered to detect differences in hard renal outcomes like dialysis initiation or doubling of creatinine.

The second limitation is the absence of long-term data. The longest controlled follow-up of TRT with renal monitoring is 5 years. Kidney disease evolves over decades. A man who starts TRT at age 55 and maintains hematocrit between 45 and 50 percent may have no measurable renal risk. But the evidence base only extends to age 60. Beyond that, extrapolation is required.

The third limitation is the lack of dose-response studies for renal outcomes. We know that higher hematocrit correlates with higher renal risk. We do not know whether a lower TRT dose that maintains hematocrit at 45 percent eliminates the risk entirely or merely reduces it. A 2021 dose-ranging study in the Journal of Clinical Endocrinology & Metabolism found that a 50 percent dose reduction reduced hematocrit by 3.2 percentage points and reduced the rate of eGFR decline by 0.4 mL/min/1.73 m² per year. That is a meaningful reduction but not zero.

The fourth limitation is the lack of validated risk prediction tools. There is no equation analogous to the Framingham score that incorporates TRT, hematocrit, and baseline eGFR to predict renal risk. Clinicians must rely on clinical judgment and serial monitoring. This is imprecise. A 2023 editorial in the American Journal of Kidney Diseases called for a multicenter registry to develop such a tool. Until then, the best approach is individualized monitoring with clear thresholds for intervention.

The final limitation is the uncertainty around testosterone's direct effect on glomerular cells in humans. The animal data suggest a threshold effect: low doses may be protective, high doses harmful. A 2015 study in the Journal of the American Society of Nephrology showed that castrated rats with low testosterone had more glomerular sclerosis than intact rats, and testosterone replacement at physiologic doses reduced sclerosis. This suggests that in hypogonadal men, restoring normal testosterone may be renoprotective, not harmful. The clinical implication is that the dose matters: replacement, not supraphysiologic dosing. The evidence for this in humans is indirect, but it is biologically plausible.

For the man asking whether TRT can cause kidney problems, the honest answer is: it can create conditions that stress the kidney, but the stress is usually manageable with monitoring. The risk is not in the molecule itself, but in the hematocrit, the blood pressure, and the fluid balance that it shifts. Control those variables, and the kidney is safe in most men. Ignore them, and the risk is real. The difference between a safe TRT course and a risky one is not the decision to start, but the discipline of surveillance. Per the 2018 AUA guideline, hematocrit monitoring every 6 months and blood pressure monitoring at every visit are the minimum standards. Cystatin C for rising creatinine is the correction that prevents the most common diagnostic error. The evidence does not support avoiding TRT out of fear of kidney damage. It supports using TRT with the same rigor applied to any therapy that shifts hemodynamics and hematologic parameters. That is the practical conclusion.